An international study: Retatrotide achieves promising results in weight loss and diabetes control

Retatrutide, which has been described as the “Godzilla” or giant of weight-loss drugs, may help improve blood sugar levels, reduce inflammation, and reduce body weight by a quarter, according to the largest study of its kind.

This drug works by mimicking three main intestinal hormones that contribute to regulating appetite, blood sugar levels, and metabolism: GLP1, GLP, and glucagon. Unlike other medications, such as “Wegovi,” which primarily targets the GLP1 pathway to suppress appetite, or “Monjaro,” which combines “GLP1” and “GLP” to control sugar levels, “Retaretide” also interacts with glucagon receptors, which helps increase the rate of energy burning, according to a report by the British newspaper “The Guardian.”

The drug has not yet received the approval of any regulatory body, but the results of the global trial that included people suffering from obesity and type 2 diabetes indicate its ability to help them get rid of large amounts of excess weight, in addition to providing other important health benefits.

The researchers said that the drug “retatrotide” showed a significant decrease in body weight, in addition to an improvement in the control of blood sugar levels and cardiac risk factors.

The results of the study, which was funded by Eli Lilly, the manufacturer of retaretide, were published in the medical journal The Lancet and presented at the annual meeting of the European Association for the Study of Diabetes in Milan, Italy.

This clinical trial included a total of 2,047 adults from eight countries: Argentina, Australia, Brazil, India, Mexico, Romania, Spain, and the United States.

Participants had type 2 diabetes and had a body mass index (BMI) of 27 or more. Women constituted 48 percent of the participants, while men constituted 52 percent, and their average age was 55 years.

In this 80-week trial (a phase III trial), participants were randomly assigned to receive a weekly injection of either a placebo (289 participants) or retaretide at doses of 4 mg (292 participants), 9 mg (284 participants), or 12 mg (287 participants), in conjunction with receiving nutritional counseling and guidance on physical activity.

By the end of the study, participants who received the 4 mg dose of Retaretide lost an average of 11.9 percent of their body weight, and this percentage increased to 16.8 percent with the 9 mg dose, and to 18.8 percent with the 12 mg dose. While the group that received the placebo lost 5.1 percent of its weight.

Among those who received the 12 mg dose, nearly half (47 percent) lost at least 20 percent of their starting weight, while nearly a third (31 percent) lost at least 25 percent; This compares to 6 percent and 3 percent, respectively, in the placebo group.

In addition, 72 percent of participants achieved a level of 6.5 percent or lower on the glycated hemoglobin (HbA1c) test, which is a measure of average blood sugar levels over the past two or three months and is considered a standard threshold for diagnosing type 2 diabetes, compared with 29 percent in the placebo group.

According to the researchers, retatrotide also significantly improved cardiometabolic risk factors, including blood pressure and blood fat levels, and reduced levels of high-sensitivity C-reactive protein, a biomarker of inflammation.

The trial witnessed seven deaths: two cases in the 4 mg dose group of “retatrotide”, three cases in the 9 mg dose group, one case in the 12 mg dose group, and one case in the placebo group. The responsible researcher considered that these deaths were not related to the therapeutic intervention under study.